Payment for cancer biomarker testing

Archives of Pathology and Laboratory Medicine

Volumn 139, Issue 3, 2015, Pages 300-304

  Allen, Timothy Craig ^a  

^a University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ECONOMICS; HUMAN; MOLECULAR DIAGNOSIS; NEOPLASM; UNITED STATES;

HUMANS; MOLECULAR DIAGNOSTIC TECHNIQUES; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84923856083     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2014-0190-ED     Document Type: Editorial

References (22)

1. Targeted cancer therapies. National Cancer Institute Web site. http://www.cancer.gov/cancertopics/factsheet/Therapy/targeted. Accessed February 19, 2014.
2. Dupere B. Companion biomarkers and cancer treatment: lessons learned for oncology new product planning. Oncol Bus Rev. September 2008:24-29. http://obroncology.com/documents/OBR-sept08-CB&CT.pdf. Accessed April 29, 2014.
3. Ross W, Lynch P, Raju G, et al. Biomarkers, bundled payments, and colorectal cancer care. Genes Cancer. 2012;3(1):16-22.
4. Schneider JE, Sidnu MK, Doucet C, Kiss N, Ohsfeld RL, Chalfin D. Economics of cancer biomarkers. Personalized Med. 2012;9:829-837.
5. Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. Br J Cancer. 2012;106(6):1100-1106.
6. Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. Arch Pathol Lab Med. 2013;137(6):828-860.
7. Meric-Bernstam F, Mills GB. Overcoming implementation challenges of personalized cancer therapy. Nat Rev Clin Oncol. 2012;9(9):542-548.
8. Shelley S. Biomarkers create opportunities, complicate drug dispensing. Pharm Commerce. July-August 2012. http://pharmaceuticalcommerce.com/brand-communications?articleid=26582. Accessed April 24, 2014.
9. Raab GG, Parr DH. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology-part 1: issues in medical device assessment. J Am Coll Radiol. 2006;3(9):694-702.
10. Trogan G. What do payers want in oncology diagnostics?: insights from a national survey of top commercial and Medicare health plans. Am Drug Health Benefits. 2011;4 (4). http://www.ahdbonline.com/issues/2011/august-2011-vol-4-no-4-special-issue/790-article-790. Accessed April 24, 2014.
11. Wish JB. Anemia management under a bundled payment policy for dialysis: a preview for the United States from Japan. Kidney Int. 2011;79(3):265-267.
12. Raab GG, Parr DH. From medical invention to clinical practice: the reimbursement challenge facing new device procedures and technology-part 2: coverage. J Am Coll Radiol. 2006;3(10):772-777.
13. Raynovich R. Biomarkers update-personalized medicine. Genet Eng Biotechnol News . http://www.genengnews.com/gen-articles/biomarkers-update-personalized-medicine/4257/. Published May 19, 2009. Accessed April 24, 2014.
14. Gottlieb S. Medicare nixes coverage for new cancer tests. Forbes. http://www.forbes.com/sites/scottgottlieb/2013/05/22/medicare-nixes-coverage-for -some-new-cancer-tests/. Published May 22, 2013. Accessed May 22, 2013.
15. Gottlieb S. Medicare has stopped paying bills for medical diagnostic tests: patients will feel the effects. Forbes . http://www.forbes.com/sites/scottgottlieb/2013/03/27/medicare-has-stopped-paying-bills-for-medical-diagnostic-tests-patients-will-feel-the-effects/2/. Published March 27, 2013. Accessed May 20, 2013.
16. Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for personalized care: cancer biomarkers and comparative effectiveness. Mol Oncol. 2012;6(2):260-266.
17. Scott MG. When do new biomarkers make economic sense? Scand J Clin Lab Invest Suppl. 2010;242:90-95.
18. Montero AJ, Avancha K, Gluck S, Lopes G. A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer. Breast Cancer Res Treat. 2012;132(2):747-751.
19. Hao Y, Thomas A. Health technology assessment and comparative effectiveness research: a pharmaceutical industry perspective. Expert Rev Pharmacoecon Outcomes Res. 2013;13(4):447-454.
20. Logue LJ. Reimbursement of tumor marker tests. Clin Chem. 1993;39(11, pt 2):2435-2438.
21. Falcone F, Marinelli M, Minguzzi L, et al. Tumor markers and lung cancer: guidelines in a cost-limited medical organization. Int J Biol Markers. 1996;11(2):61-66.
22. Allen TC. "Evidence-based" medical malpractice research and changing the patient safety paradigm. Bull Health Policy Law. 2012:1(1):e2.